Free Trial

Inotiv Q2 2024 Earnings Report

Inotiv logo
$3.78 -0.17 (-4.30%)
(As of 12:40 PM ET)

Inotiv EPS Results

Actual EPS
-$0.29
Consensus EPS
$0.05
Beat/Miss
Missed by -$0.34
One Year Ago EPS
N/A

Inotiv Revenue Results

Actual Revenue
$119.04 million
Expected Revenue
$136.74 million
Beat/Miss
Missed by -$17.70 million
YoY Revenue Growth
N/A

Inotiv Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Conference Call Audio

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Inotiv Earnings Headlines

Inotiv Shares Drop on $25.5 Mln Public Offering
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares
Combine the QQQ, IWM and SPY in one trade
If you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…
Inotiv prices 6M shares at $4.25 in underwritten public offering
Inotiv, Inc. Launches Proposed Public Offering of Common Shares
Craig-Hallum Releases a Buy Rating on Inotiv (NOTV)
See More Inotiv Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inotiv? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inotiv and other key companies, straight to your email.

About Inotiv

Inotiv (NASDAQ:NOTV) provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

View Inotiv Profile

More Earnings Resources from MarketBeat

Upcoming Earnings